



**PERSONAL INFORMATION**

Name

**CHIARI RITA**

Address

Telephone

Fax

E-mail

Nationality

Date of birth

**PRESENT POSITION**

- Dates (from – to)
- Name and address of employer
- Type of business or sector
- Occupation or position held
- Main activities and responsibilities

**1<sup>st</sup> December 2021 – ongoing**

“Azienda Ospedaliera- Ospedali Riuniti Marche Nord– Division of Medical Oncology  
Oncology  
Direttore UOC Oncologia  
Specialist in Oncology

**PREVIOUS POSITION**

- Dates (from – to)
- Name and address of employer
- Type of business or sector
- Occupation or position held
- Main activities and responsibilities

**15<sup>th</sup> January 2019 – November 2021**

“Ospedali Riuniti Padova Sud+Ospedali di Piove di Sacco” AULSS6 Euganea (Padova)-  
Director of the division of Medical Oncology “Padova Sud”  
Oncology  
Direttore UOC Oncologia  
Specialist in Oncology

- June 2005 – December 2018. Clinical Oncology and clinical research activity as sub-investigator mainly on “Thoracic Oncology” - Oncology Department “Santa Maria della Misericordia” Hospital- Perugia
- December 2002 – June 2005: Clinica. I Oncology and clinical research activity - Oncology Department - “Santa Maria” Hospital -Terni

- January 2000 – December 2002 : Clinical Oncology and Research activity on Tumor Immunology, Institute of Internal Medicine and Oncological Sciences-University of Perugia – Italy
- March 1997- December 1999 : Basic and clinical Research activity on Tumor Immunology at the Ludwig Institute for Cancer Research, Brussel Branch
- November 1996-February 1997 : Research activity on Signal Transduction at the European Institute of Oncology, Milan, Italy
- November 1993-November 1996: Clinical Oncology and Research activity on Signal Transduction, Institute of Internal Medicine and Oncological Sciences-University of Perugia - Italy

## EDUCATION AND TRAINING

• Dates (from – to)

- June 2005- present: Consultant in Oncology at Ospedale Sivestrini – Perugia - Italy
- February 2002 - June 2005 : Consultant in Oncology at Ospedale S.Maria – Terni - Italy.
- December 2002 – August 2003: “Ricercatore Universitario” – Institute of Internal Medicine University of Perugia – Section of Terni - Italy .
- November 2001 – December 2002: Fellowship in Molecular Biology - Institute of Internal Medicine and Oncological Sciences - University of Perugia – Italy.
- November 1998 - November 2001: Specialist registrar training program in Medical Oncology - Institute of Internal Medicine and Oncological Sciences - University of Perugia – Italy.
- March 1997- December 1999: Post-doctoral fellow at the Ludwig Institute for Cancer Research- Brussel Branch
- June 1998: PhD in Medical Oncology with full marks, University of Modena - Italy
- 1993:Medical Doctor with full marks (110/110 cum laude), University of Perugia
- 1987:Secondary school diploma with full marks, Liceo Scientifico G.Alessi, Perugia

## PRIZES AND MEMBERSHIP

- Since 2004 Member of Italian Association in Medical Oncology (AIOM).
- 1998-99 Prize for Research of the Italian Society of Internal Medicine

## DIDACTICS

- From November 2012- present: Oncology – 2nd year of Nursery School – University of Perugia – Section of Perugia
- From November 2002 to November 2005: Oncology – 3rd year of Medical School – University of Perugia – Section of Terni

## MOTHER TONGUE

[ Italian ]

## OTHER LANGUAGES

- Reading skills
- Writing skills
- Verbal skills

[ English ]

[ excellent.]

[ excellent]

[ excellent]

- *Reading skills*
- *Writing skills*

[ French ]

[ excellent]

[ good]

• Verbal skills [ excellent.]

## SOCIAL SKILLS AND COMPETENCES

*Living and working with other people, in multicultural environments, in positions where communication is important and situations where teamwork is essential (for example culture and sports), etc.*

[ I have a particular attitude towards team-working. In the team I almost always have a central position stimulating other people to make their part ]

## SCIENTIFIC PUBLICATIONS

---

**2020** - Gobbini E., **Chiari R.**, Pizzutillo P., Bordi P., Ghilardi L., Pilotto S., Osman G., Cappuzzo F., Cecere F., Riccardi F., Scotti V., Martelli O., Borra G., Maiello E., Rossi A., Graziano P., Gregorc V., Casartelli C., Sergi C., Del Conte A., Delmonte A., Bareggi C., Cortinovis D., Rizzo P., Tabbò F., Rossi G., Bria E., Galetta D., Tiseo M., Di Maio M., Novello S. Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study

ISSN: 1699048X Clinical and Translational Oncology Volume 22, Issue 3, 1 March 2020, Pages 294-301 DOI: 10.1007/s12094-019-02222-8

---

**2020** - Cortellini A., Bersanelli M., Santini D., Buti S., Tiseo M., Cannita K., Perrone F., Giusti R., De Tursi M., Zoratto F., Marconcini R., Russano M., Zeppola T., Anesi C., Filetti M., Marchetti P., Botticelli A., Gelibter A., De Galitiis F., Vitale M.G., Rastelli F., Tudini M., Silva R.R., Atzori F., **Chiari R.**, Ricciuti B., De Giglio A., Migliorino M.R., Mallardo D., Vanella, V., Mosillo C., Bracarda S., Rinaldi S., Berardi R., Natoli C., Ficorella C., Porzio G., Ascierio P.A.

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events (IF: 6.15)

ISSN: 09598049 European Journal of Cancer Volume 128, March 2020, Pages 17-26 DOI: 10.1016/j.ejca.2019.12.031

---

**2020** - Franceschini D., Bruni A., Borghetti P., Gaj-Levra N., Ramella S., Buffoni L., Badellino S., Andolina M., Comin C., Vattei E., Bezzi M., Trovò M., Passaro A., Bearz A., **Chiari R.**, Tindara F., Ferrari K., Piperno G., Filippi A.R., Genovesi D., Scotti V. Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings (IF: 1.82)

ISSN: 00338362 Radiologia Medica Volume 125, Issue 2, 1 February 2020, Pages 214-219 DOI: 10.1007/s11547-019-01094-w

---

**2020** - Reale M.L., **Chiari R.**, Tiseo M., Vitiello F., Barbieri F., Cortinovis D., Ceresoli G., Finocchiaro G., Romano G.D., Piovano P.L., Del Conte A., Borra G., Verderame F., Scotti V., Nonnis D., Galetta D., Sergi C., Migliorino M.R., Tonini G., Cecere F., Berardi R., Pino M.S., Martelli O., Gelibter A., Carta A., Vattei E., Pagano M., Zullo A., Ferrari S., Rossi A., Novello S.

Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients (IF:4.52)

ISSN: 01695002 Lung Cancer Volume 140, February 2020, Pages 71-79 DOI: 10.1016/j.lungcan.2019.12.006

---

**2020** - Ricciuti B., Lamberti G., Andrini E., Genova C., De Giglio, A., Bianconi V, Sahebkar A., **Chiari R.**, Pirro M. Antibody–drug conjugates for lung cancer in the era of personalized oncology (IF:8.86)

ISSN: 1044579X Seminars in Cancer Biology DOI: 10.1016/j.semcancer.2019.12.024

---

**2020** - **Chiari R.**, Ricciuti B., Landi L, Morelli A. M., Delmonte A, Spitaleri G, Cortinovis D. L., Lamberti G, Facchinetti F., Pilotto S, Verusio C, Chella A, Bonanno L, Galetta D, Cappuzzo F

ROS1-rearranged non-small cell lung cancer is associated with high rate of venous thromboembolism: analysis from a phase II, prospective, multicentre, two-arms trial (METROS) (IF:3,66)

ISSN: 15257304 Clinical Lung Cancer Volume 21, Issue 1, January 2020, Pages 15-20 DOI: 10.1016/j.clcc.2019.06.012

---

**2020** - Naqash A.R., Ricciuti B., Owen D.H., Florou V., Toi Y., Cherry C., Hafiz M., De Giglio A., Muzaffar M., Patel S.H., Sugawara S., Burkart J., Park W.e, **Chiari R.**, Sugisaka J., Otterson G.A., de Lima Lopes G., Walker P.R.

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

ISSN: 03407004 Cancer Immunology, Immunotherapy DOI: 10.1007/s00262-020-02536-5 (IF: 4.86)

- 
- 2019** - Landi L., D'Inca F., Gelibter A., **Chiari R.**, Grossi F., Delmonte A., Passaro A., Signorelli D., Gelsomino F., Galetta D., Giannarelli D., Soto Parra H., Minuti G., Tiseo M., Migliorino M.R., Cognetti F., Toschi L., Bidoli P., Piantedosi F., Calabro L., Cappuzzo F.  
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer  
ISSN: 20511426 Journal for ImmunoTherapy of Cancer Volume 7, Issue 1, 21 November 2019, Article number 316 DOI: 10.1186/s40425-019-0793-8 (IF: 6,86)
- 
- 2019** - Abate R.E., Pasquale R., Sacco A., Piccirillo M.C., Morabito A., Bidoli P., Finocchiaro G., **Chiari R.**, Foltran L., Buosi R., Tiseo M., Giannetta L., Battiloro C., Fasola, G., Romano G., Ciuffreda L., Frassoldati A., Marinis F.D., Cappuzzo F., Normanno N.  
Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib  
ISSN: 20726694 Cancers Volume 11, Issue 10, October 2019, Article number 1431 DOI: 10.3390/cancers11101431 (IF: 5.87)
- 
- 2019** - Anna Paola Mariniello, Eleonora Ghisoni, Luisella Righi, Annamaria Catino, **Rita Chiari**, Alessandro Del Conte, Fausto Barbieri, Fabiana Cecere, Alain Gelibter, Matteo Giajlevra, Hector Soto Parra, Clizia Zichi, Massimo Di Maio, Giorgio Valabrega And Silvia Novello  
Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report  
ISSN: 0258-851X In Vivo Volume 33, Issue 6, 2019, Pages 2021-2026 DOI: 10.21873/invivo.11699 (IF: 1.50)
- 
- 2019** - Ferrer L, Giaj Levra M, Brevet M, Antoine M, Mazieres J, Rossi G, **Chiari R**, Westeel V, Poudenx M, Letreut J, Gervais R, Osman G, Girard N, Toffart A.C, Novello S, Moro-Sibilot D  
A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics  
ISSN: 1556-0864 Journal of Thoracic Oncology Volume 14, Issue 1, January 2019, Pages 130-134 (IF: 5.71)  
DOI:10.1016/j.jtho.2018.08.2028
- 
- 2019** - Rossana Berardi, Candida Mastroianni, Giuseppe Lo Russo, Roberta Buosi, Daniele Santini, Agnese Montanino, Carlo Carnaghi, Marcello Tiseo, **Rita Chiari**, Andrea Camerini, Sandro Barni, Valeria De Marino, Daris Ferrari, Antonella Cristofano, Laura Doni, Federica Freddari, Daniele Fumagalli, Luigi Portalone, Roberta Sarmiento, Giovanni Schinzari, Francesca Sperandi, Marcello Tucci, Alessandro Inno, Libero Ciuffreda, Marita Mariotti, Cinzia Mariani, Miriam Caramanti, Mariangela Torniai, Rosaria Gallucci, Chiara Bennati, Paola Bordi, Lucio Buffoni, Achille Galeassi, Michele Ghidini, Emidio Grossi, Alessandro Morabito, Bruno Vincenzi and Emanuela Arvat (IF: 5.44)  
Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study  
ISSN: 1758-8340 Clinical Lung Cancer Therapeutic Adv Med Oncol 2019, Vol. 11: 1–13 DOI: 10.1177/1758835919877725
- 
- 2019** - Pérol M., Pavlakis N., Levchenko E., Platania M., Oliveira J., Novello S., **Chiari R.**, Moran T., Mitry E., Nüesch E., Liu T., Balas B., Konopa K., Peters S.  
Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (IF: 4.52)  
ISSN: 01695002 Lung Cancer, Volume 138, December 2019, Pages 79-87 DOI: 10.1016/j.lungcan.2019.10.002
- 
- 2019** - Cortellini A, Leonetti A, Catino A, Pizzutillo P, Ricciuti B, De Giglio A, **Chiari R**, Bordi P, Santini D, Giusti R, De Tursi M, Brocco D, Zoratto F, Rastelli F, Citarella F, Russano M, Filetti M, Marchetti P, Berardi R, Torniai M, Cortinovis D, Sala E, Maggioni C, Follador A, Macerelli M, Nigro O, Tuzi A, Iacono D, Migliorino M.R, Banna G, Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes (IF: 2,932)  
ISSN: 1699048X Clinical and Translational Oncology DOI: 10.1007/s12094-019-02193-w
- 
- 2019** - Ricciuti B, Brambilla M, Cortellini A, De Giglio A, Ficorella C, Sidoni A, Bellezza G, Crinò L, Ludovini V, Baglivo S, Metro G, **Chiari R**  
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. (IF: 2,932)  
ISSN: 1699048X Clinical and Translational Oncology DOI: 10.1007/s12094-019-02175-y
- 
- 2019** - Passiglia F, Cappuzzo F, Alabiso O, Bettini AC, Bidoli P, **Chiari R**, Defferrari C, Delmonte A, Finocchiaro G, Francini G, Gelsomino F, Giannarelli D, Giordano M, Illiano A, Livi L, Martelli O, Natoli C, Puppo G, Ricevuto E, Roca E, Turci D, Galetta D.  
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. (IF: 5,922)  
ISSN: 00070920 British Journal Cancer 2019 Jan;120(1): 57-62. doi: 10.1038/s41416-018-0234-3. Epub 2018 Oct 31.  
PMID: 30377342
- 
- 2019** - Alice T Shaw, Benjamin J Solomon, Rita Chiari, Gregory J Riely, Benjamin Besse, Ross A Soo, Steven Kao, Chia-Chi Lin, Todd M Bauer, Jill S Clancy, Holger Thurm, Jean-Francois Martini, Gerson Peltz, Antonello Abbattista, Sherry Li, Sai-Hong Ignatius Ou  
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial  
ISSN: 14702045 The Lancet Oncology, Volume 20, Issue 12, December 2019, Pages 1691-1701 DOI: 10.1016/S1470-2045(19)30655-2 (IF: 10.07)
-

- 2019** - Mandarano M, Bellezza G, Belladonna ML, Van den Eynde BJ, **Chiari R**, Vannucci J, Mondanelli G, Ludovini V, Ferri I, Bianconi F, Del Sordo R, Cagini L, Albini E, Metro G, Puma F, Sidoni A.  
Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. (IF: 2,848) ISSN: 09456317  
*Virchows Archiv* 2019 Feb;474(2):159-168. doi: 10.1007/s00428-018-2483-1. Epub 2018 Nov 17. PMID: 30448912
- 
- 2019** - Ricciuti B, Genova C, De Giglio A, Bassanelli M, Dal Bello MG, Metro G, Brambilla M, Baglivo S, Grossi F, **Chiari R**.  
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. (IF: 3,081)  
ISSN: 01715216 *Journal of Cancer Research and Clinical Oncology* 2019 Feb;145(2):479-485. doi: 10.1007/s00432-018-2805-3. Epub 2018 Dec 1. PMID: 30506406
- 
- 2019** - Ricciuti B, Leonardi GC, Puccetti P, Fallarino F, Bianconi V, Sahebkar A, Baglivo S, **Chiari R**, Pirro M.  
Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence. (IF: 9,39)  
ISSN: 01637258 *Pharmacology and Therapeutics* 2019 Apr;196:105-116. doi: 10.1016/j.pharmthera.2018.12.004. Epub 2018 Dec 4. Review. PMID: 30521884
- 
- 2019** - Ludovini V, Ricciuti B, Tofanetti FR, Mencaroni C, Giannarelli D, Sidoni A, Reda MS, Siggillino A, Baglivo S, Crinò L, Bellezza G, **Chiari R**, Metro G.  
KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer. (IF: 5,962) ISSN: 20499450  
*Molecular and Clinical Oncology* 2018 Dec;9(6):689-696 doi: 10.3892/mco.2018.1731 Epub 2018 Oct 1. PMID:30546903
- 
- 2019** - Passaro A, Prelaj A, Bonanno L, Tiseo M, Tuzi A, Proto C, **Chiari R**, Rocco D, Genova C, Sini C, Cortinovis D, Pilotto S, Landi L, Bennati C, Camerini A, Toschi L, Putzu C, Cerea G, Spitaleri G, Cappuzzo F, de Marinis F. (IF: 4,117)  
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. ISSN: 15257304 *Clinical Lung Cancer* 2019 Mar;20(2):e186-e194. doi: 10.1016/j.clcc.2018.11.005. Epub 2018 Nov 20. PMID: 30563752
- 
- 2019** - **Chiari R**, Sidoni A, Metro G.  
Early stage resectable non-small cell lung cancer: is neoadjuvant immunotherapy the right way forward? (IF: 2,027)  
ISSN: 20721439 *Journal of Thoracic Disease* 2018 Nov;10(Suppl 33):S3890-S3894. doi: 10.21037/jtd.2018.10.22. PMID: 30631508
- 
- 2019** - Ulivi P, Petracci E, Marisi G, Baglivo S, **Chiari R**, Billi M, Canale M, Pasini L, Racanicchi S, Vagheggi A, Delmonte A, Mariotti M, Ludovini V, Bonafè M, Crinò L, Grignani F.  
Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer. (IF: 5,02)  
ISSN: 20770383 *Journal of Clinical Medicine* 2019 Jan 23;8(2). pii: E131. doi: 10.3390/jcm8020131. PMID: 30678026
- 
- 2019** - Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, Bersanelli M, Michiara M, Grassadonia A, Brocco D, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Sabbatini R, Bracarda S, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, **Chiari R**, Ricciuti B, Iacono D, Migliorino MR, Rossi A, Porzio G, Cannita K, Ciciarelli V, Fargnoli MC, Ascierto PA, Ficarella C.  
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. (IF: 2,98) ISSN: 10837159  
*Oncologist*. 2019 Jun;24(6):e327-e337. doi: 10.1634/theoncologist.2018-0618. Epub 2019 Feb 22. PMID: 30796151
- 
- 2019** - Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, **Chiari R**, Ricciuti B, De Giglio A, Iacono D, Gelibter A, Occhipinti MA, Parisi A, Porzio G, Fargnoli MC, Ascierto PA, Ficarella C, Natoli C.  
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. (IF: 8,676) ISSN: 20511426  
*Journal for ImmunoTherapy of Cancer*. 2019 Feb 27;7(1):57. doi: 10.1186/s40425-019-0527-y. PMID: 30813970
- 
- 2019** - Bianconi F, Palumbo I, Fravolini ML, **Chiari R**, Ministrini M, Brunese L, Palumbo B.  
Texture Analysis on [18F]FDG PET/CT in Non-Small-Cell Lung Cancer: Correlations Between PET Features, CT Features, and Histological Types. (IF: 1,942)  
ISSN:15361632 *Molecular Imaging Biology* 2019 Mar 7. doi: 10.1007/s11307-019-01336-3. PMID: 30847822
- 
- 2019** - Cortellini A, **Chiari R**, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, Grassadonia A, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Porzio G, Cannita K, Ficarella C, Buti S.  
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. (IF:4,117)  
ISSN: 15257304 *Clinical Lung Cancer*. 2019 Jul;20(4):237-247.e1. doi: 10.1016/j.clcc.2019.02.006. Epub 2019 Feb 21. PMID: 30885550
-

**2019** - Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, Riely GJ, Ou SI, Clancy JS, Li S, Abbattista A, Thurm H, Satouchi M, Camidge DR, Kao S, **Chiari R**, Gadgeel SM, Felip E, Martini JF.

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. (IF: 28,245)

ISSN: 0732183X Journal of Clinical Oncology 2019 Jun 1;37(16):1370-1379. doi: 10.1200/JCO.18.02236. Epub 2019 Mar 20. PMID: 30892989

---

**2019** - Ricciuti B, Genova C, Bassanelli M, De Giglio A, Brambilla M, Metro G, Baglivo S, Dal Bello MG, Ceribelli A, Grossi F, **Chiari R**.

Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression.

ISSN: 15257304 Clinical Lung Cancer. 2019 May;20(3):178-185.e2. doi: 10.1016/j.clcc.2019.02.001. Epub 2019 Feb 27. PMID: 30910574 (IF:4,117)

---

**2019** - Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, Kendra K, Ricciuti B, **Chiari R**, De Giglio A, Sleiman J, Funchain P, Wills B, Zhang J, Naidoo J, Philpott J, Gao J, Subudhi SK, Wang Y.

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. (IF: 28,245)

ISSN: 0732183X Journal of Clinical Oncology 2019 Jun 4;JCO1900320. doi: 10.1200/JCO.19.00320. PMID: 31163011

---

**2019** - Capelletto E, Migliorino MR, Morabito A, **Chiari R**, Grossi F, Tiseo M, Costanzo FD, Delmonte A, Romano G, Galetta D, Scotti V, Gregorc V, Pisconti S, Ceresoli GL, Conte AD, Ciuffreda L, Colantonio I, Bria E, Ricciardi S, Manzo A, Metro G, Morelli AM, Critelli R, Pacchiana MV, Stura I, Migliaretti G, Novello S.

Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. (IF: 4,599) ISSN: 01695002 Lung Cancer. 2019 Aug;134:210-217. doi: 10.1016/j.lungcan.2019.06.028. Epub 2019 Jun 27. PMID: 31319983

---

**2019** - Cortinovis D, **Chiari R**, Catino A, Grossi F, DE Marinis F, Sperandi F, Piantedosi F, Vitali M, Parra HJS, Migliorino MR, Tondini C, Tassinari D, Frassoldati A, Verderame F, Pazzola A, Cognetti F, Palmiotti G, Marchetti P, Santoro A, Giannarelli D, Colonese F, Delmonte A. (IF: 1,865)

Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases.

ISSN: 02507005 Anticancer Research 2019 Aug; 39(8):4265-4271. doi: 10.21873/anticancer.13590. PMID: 31366516

---

**2019** - Landi L, **Chiari R**, Tiseo M, D'Inca F, Dazzi C, Chella A, Delmonte A, Bonanno L, Giannarelli D, Cortinovis DL, De Marinis F, Borra G, Morabito A, Gridelli C, Galetta D, Barbieri F, Grossi F, Capelletto E, Minuti G, Mazzoni F, Verusio C, Bria E, Ali G, Bruno R, Proietti A, Fontanini G, Crinò L, Cappuzzo F.

Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial. (IF: 8,372)

ISSN: 1078-0432 Clinical Cancer Research 2019 Aug 15. pii: clincanres.0994.2019. doi: 10.1158/1078-0432.CCR-19-0994. PMID: 31416808

---

**2019** - Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT.

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. (IF: 35,38)

ISSN: 14702045 The Lancet Oncology 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6. Erratum in: Lancet Oncol. 2019 Jan;20(1):e10. PMID: 30413378

---

**2018** - Ricciuti B, Marcomigni L, Metro G, Bellezza G, Caselli E, Baglivo S, **Chiari R**.

Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib (IF:12,46)

ISSN: 15560864 Journal of Thoracic Oncology 2018 Nov;13(11):e220-e222 doi: 10.1016/j.jtho.2018.05.035 PMID: 30368411

---

**2018** - Ricciuti B, Baglivo S, De Giglio A, **Chiari R**

Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience. (IF: 3,286)

ISSN: 17534658 Therapeutic Advances in Respiratory Diseases 2018 Jan-Dec;12:1753466618808659. doi: 10.1177/1753466618808659.

---

**2018** - Metro G, Baglivo S, Siggillino A, Ludovini V, **Chiari R**, Rebonato A, Bellezza G4

Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient. (IF: 2,158)

ISSN: 11732563 Clinical Drug Investigation 2018 Oct;38(10):983-987 doi: 10.1007/s40261-018-0691-8.

---

**2018** - Ferrer, Giaj Levra, Brevet M, Antoine M, Mazieres J, Rossi G, **Chiari R**, Westeel V, Poudenx M, Letreut J, Gervais R, Osman G, Girard N, Toffart AC, Novello S, Moro-Sibilot D. (IF: 12,46)

A brief report of transformation from Non-small cell to small cell lung cancer: Molecular and therapeutic characteristics.

ISSN: 15560864 Journal of Thoracic Oncology 2018 Sep 11. pii: S1556-0864(18)33044-2 doi: 10.1016/j.jtho.2018.08.2028

---

**2018** - Umberto Malapelle, Biagio Ricciuti, Sara Baglivo, Francesco Pepe, Pasquale Pisapia, Paola Anastasi, Marco Tazza, Angelo Sidoni, Anna M. Liberati, Guido Bellezza, **Rita Chiari** and Giulio Metro

Osimertinib. (IF: 1,86)

ISSN: 0080-0015 Recent Results Cancer Research. 2018;211:257-276 - doi: 10.1007/978-3-319-91442-8\_18 -

---

**2018** - Metro G, Giannarelli D, Sidoni A, **Chiari R**, Bellezza G

Anaplastic lymphoma kinase immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients. (IF:1.449)

Int J Biol Markers. 2018 Apr 1;1724600818754763. doi: 10.1177/1724600818754763 - ISSN: 17246008

**2018** - Montedori A, Bidoli E, Serraino D, Fusco M, Giovannini G, Casucci P, Franchini D, Granata A, Ciullo V, Vitale MF, Gobbato M, **Chiari R**, Cozzolino F, Orso M, Orlandi W, Abraha I; D.I.V.O. Group

Accuracy of lung cancer ICD-9-CM codes in Umbria, Napoli 3 Sud and Friuli Venezia Giulia administrative healthcare databases: a diagnostic accuracy study.

BMJ Open. 2018 May 17;8(5):e020628. doi: 10.1136/bmjopen-2017-020628. Online ISSN: 2044-6055 (IF:2.413)

**2018** - Abraha I, Serraino D, Montedori A, Fusco M, Giovannini G, Casucci P, Cozzolino F, Orso M, Granata A, De Giorgi M, Collarile P, **Chiari R**, Foglietta J, Vitale MF, Stracci F, Orlandi W, Bidoli E; D.I.V.O. Group

Sensitivity and specificity of breast cancer ICD-9-CM codes in three Italian administrative healthcare databases: a diagnostic accuracy study.

BMJ Open. 2018 Jul 23;8(7):e020627. doi: 10.1136/bmjopen-2017-020627. Online ISSN: 2044-6055 (IF:2.413)

**2018** - Baglivo S, Ricciuti B, Ludovini V, Metro G, Siggillino A, De Giglio A, **Chiari R**

Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation

Journal of Thoracic Oncology 13(8), pp. e145-e147 ISSN: 15560864 DOI: 10.1016/j.jtho.2018.03.017 (IF:5,02)

**2018** - Garassino M.C, Gelibter A.J, Grossi F, **Chiari R**, Soto Parra H, Cascinu S, Cognetti F, Turci D, Blasi L, Bengala C, Mini E, Baldini E, Quadri S, Ceresoli G.L, Antonelli P, Vasile E, Pinto C, Fasola G, Galetta D, Macerelli M, Giannarelli D, Lo Russo G Lo Russo G, de Marinis F Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients

Journal of Thoracic Oncology 13(8), pp. 1146-1155 - ISSN: 15560864 DOI: 10.1016/j.jtho.2018.04.025 (IF: 5,02)

**2018** - Biagio Ricciuti, Sara Baglivo, Vienna Ludovini, Angelo Sidoni, Giulio Metro, Marta Brambilla, Annamaria Siggillino, Maria Sole Reda, Alberto Rebonato, Daniele Maiettini, **Rita Chiari**

Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations. Lung Cancer ISSN: 01695002 DOI: 10.1016/j.lungcan.2018.04.002 (IF:4,45)

**2018** - Ricciuti B, De Giglio A, Mecca C, Arcuri C, Marini S, Metro G, Baglivo S, Sidoni A, Bellezza G, Crinò L, **Chiari R**

Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib

Medical Oncology 35(5),72 ISSN: 13570560 DOI: 10.1007/s12032-018-1133-4 (IF:2.63)

**2018** - Ricciuti B., **Chiari R**.

First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC

Translational Lung Cancer Research 7, pp. S127-S130 ISSN: 22186751 DOI: 10.21037/tlcr.2018.03.06 (IF:4.2)

**2018** - De Giglio A, Porreca R, Brambilla M, Metro G, Prosperi E, Bellezza G, Pirro M, **Chiari R**, Ricciuti B

Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter? Thrombosis Research DOI: 10.1016/j.thromres.2017.12.004 - ISSN: 00493848 (IF:2.65)

**2018** - Gobbini E, Pilotto S, Pasello G, Polo V, Di Maio M, Arizio F, Galetta D, Petrillo P, **Chiari R**, Matocci R, Di Costanzo A, Di Stefano TS, Aglietta M, Cagnazzo C, Sperduti I, Bria E, Novello S

Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer Clinical Lung Cancer DOI: 10.1016/j.clcc.2017.10.012 - ISSN: 15257304 (IF:3.434)

**2018** - Metro G, Passaro A, Lo Russo G, Bonanno L, Giusti R, Gregorc V, Capelletto E, Martelli O, Cecere FL, Giannarelli D Luciani A, Bearz A, Tuzi A, Scotti V, Tonini G, Galetta D, Carta A, Soto Parra H, Rebonato A, Morabito A, **Chiari R**

Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

Future Oncology DOI: 10.2217/fon-2017-0441 ISSN: 14796694 (IF:2.131)

**2018** - Ricciuti, B. Foglietta, J., **Chiari, R.**, Sahebkar, A., Banach, M., Bianconi, V., Pirro, M.

Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications

Medical Oncology DOI: 10.1007/s12032-017-1064-5 ISSN: 1357-0560 (IF:2.634)

**2018** - Ricciuti, B., Metro, G., Brambilla, M., Ludovini, V., Baglivo, S., Siggillino, A., Prosperi, E., **Chiari, R.**

Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma

Journal of Thoracic Oncology DOI: 10.1016/j.jtho.2017.08.025 ISSN: 1556-0864 (IF:6.595)

**2017** - Soria J-C, Tan DSW, **Chiari R**, Wu Y-L, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu C-J, Hochmair M, Cortot AB, Tsai C-M, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

The Lancet, ISSN: 0140-6736 - (2017) DOI: 10.1016/S0140-6736(17)30123-X 2-s2.0-85010189205 (IF:44.002)

**2017** - Tiseo M., Boni L., Ambrosio F., Camerini A., Baldini E., Cinieri S., Brighenti M., Zanelli F., Defraia E., **Chiari R.**, Dazzi C., Tibaldi C., Turolla G. M., D'alessandro V., Zilembo N., Trolese A. R., Grossi F., "Italian Multicenter Phase III Randomized Study of Cisplatin-Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive- Stage Small-Cell Lung Cancer (SCLC): GOIRC-AIFA FARM6PMFJM Trial,"

Journal of Clinical Oncology, ISSN: 0732-183X, doi: 10.1200/JCO.2016.69.4844 (IF:20.982)

**2017** - Metro G, Tazza M, Matocci R, **Chiari R**, Crinò L (2017)

Optimal management of ALK-positive NSCLC progressing on crizotinib.

Lung Cancer, ISSN: 0169-5002 2017, Vol. 106, 58-66 DOI: 10.1016/j.lungcan.2017.02.003 (IF:3.767)

**2017** - Metro G, Ricciuti B, Brambilla M, Baglivo S, Soli I, Minenza E, Leonardi GC, D'arpino A, Colabrese D, Tazza M, Zicari D, Minotti V, **Chiari R**.

The safety of nivolumab for the treatment of advanced non-small cell lung cancer.

Expert Opinion On Drug Safety, ISSN: 1474-0338 2017 Jan;16(1):101-109. (IF:2.896)

**2017** - Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi M, Capelli L, Casanova C, De Luigi N, Mariotti M, Gamboni A, **Chiari R**, Bennati C, Calistri D, Ludovini V, Crinò L, Amadori D, Ulivi P

Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.

Clinical Cancer Res. 2016 Oct 25. pii: clincanres.0966.2016. DOI: 10.1158/1078-0432.CCR-16-0966 (IF:9.619)

**2017** - Biagio Ricciuti, Marta Brambilla, Giulio Metro, Sara Baglivo, Roberta Matocci, Matteo Pirro, **Rita Chiari**

Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. (IF:2.634)

Medical Oncology, ISSN: 1357-0560

**2017** - Vienna Ludovini, **Rita Chiari**, Lorenzo Tomassoni, Chiara Antonini, Elisa Baldelli, Sara Baglivo, Annamaria Sigillino, Francesca Romana Tofanetti, Guido Bellezza, K. Alex Hodge, Emanuel Petricoin, Mariaelena Pierobon, Lucio Crinò and Fortunato Bianconi

Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non-small cell lung cancer (NSCLC): a pilot study (IF:5.168)

Oncotarget ISSN: 19492553 DOI: 10.18632/oncotarget.18480

**2017** - S. Baglivo, V. Ludovini, A. Sidoni, G. Metro B. Ricciuti, A. Siggillino, A. Rebonato, S. Messina, L. Crinò, **R Chiari**, Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer (IF:6.686)

Mayo Clinic Proceedings. 2017;pag.:1304-1311 vol. 92(8) DOI: 10.1016/j.mayocp.2017.03.022 ISSN: 00256196

**2017** - Biagio Ricciuti, Marta Brambilla, Andrea De Giglio, Giulio Metro, Roberta Porreca, **Rita Chiari**, Luca Paglialunga Therapeutic approach to brain metastasis in high-grade neuroendocrine carcinomas of the lung: where do we stand? ISSN: 1948-7894 Journal of Radiation Oncology DOI 10.1007/s13566-017-0293-8

**2017** - Ricciuti B, Baglivo S, Paglialunga L, De Giglio A, Bellezza G, Chiari R, Crinò L, Metro G.

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Therapeutic Advances in Medical Oncology 2017 Jun;9(6):387-404. doi: 10.1177/1758834017702820. Epub 2017 Apr 16 (IF:6.294)

**2017** - Ricciuti B, Metro G, Baglivo S, Colabrese D, **Chiari R**, Bennati C, Paglialunga L. (IF:6.595)

Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient. Journal of Thoracic Oncology 2017 May;12(5):e51-e55. doi: 10.1016/j.jtho.2016.12.027

**2016** - Metro G, Bellezza G, Puma F, **Chiari R**. (IF:2.094)

How might treatment of ALK-positive non-small cell lung cancer change in the near future?

Expert Review Of Anticancer Therapy, vol. 16, p. 997-999, ISSN: 1473-7140, doi: 10.1080/14737140.2016.1226138

**2016** - Ricciuti B, Metro G, Leonardi GC, Sordo RD, Colella R, Puma F, Ceccarelli S, Potenza R, Rebonato A, Maiettini D, Crinò L, **Chiari R**.

Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland.

Tumori 2016 Nov 11;102(Suppl. 2). doi: 10.5301/tj.5000514. (IF:1.071)

**2016** - Ricciuti B, Leonardi GC, Ravaioli N, De Giglio A, Brambilla M, Prosperi E, Ribacchi F, Meacci M, Crinò L, Maiettini D, **Chiari R**, Metro G.

Ductal Breast Carcinoma Metastatic to the Stomach Resembling Primary Linitis Plastica in a Male Patient.

Journal Of Breast Cancer, ISSN: 1738-6756. 2016 Sep;19(3):324-329. (IF 2015:2.46)

**2016** - Cappuzzo F, Morabito A, Normanno N, Bidoli P, Del Conte A, Giannetta L, Montanino A, Mazzoni F, Buosi R, Burgio MA, Cerea G, **Chiari R**, Cortinovis D, Finocchiaro G, Foltran L, Migliorino MR, Tiseo M, Ferrari S, De Marinis F. Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. LUNG Cancer, ISSN: 0169-5002 2016 Sep;99:31-7. doi: 10.1016/j.lungcan.2016.06.008 (IF:3.767)

**2016** - Metro G, Lunardi G, Bennati C, Chiarini P, Sperduti I, Ricciuti B, Marcomigni L, Costa C, Crinò L, Floridi P, Gori S, **Chiari R**.



Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series.  
*Journal Of Neuro-Oncology*, ISSN: 0167-594X 2016 Sep;129(2):355-61. doi: 10.1007/s11060-016-2184-z. (IF:2.754)

---

**2016** - Ricciuti B, **Chiari R**, Chiarini P, Crinò L, Maiettini D, Ludovini V, Metro G.

Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer.

*Clinical Drug Investigation*, ISSN: 1173-2563 2016 Aug;36(8):683-6. doi: 10.1007/s40261-016-0411-1. (IF:0.91)

---

**2016** - Ludovini V, Bianconi F, Siggillino A, Piobbico D, Vannucci J, Metro G, **Chiari R**, Bellezza G, Puma F, Della Fazia MA, Servillo G, Crinò L.

Gene identification for risk of relapse in stage I lung adenocarcinoma patients: a combined methodology of gene expression profiling and computational gene network analysis.

*Oncotarget*, vol. 7, p. 30561-30574, ISSN: 1949-2553 doi: 10.18632/oncotarget.8723. (IF:5.008)

---

**2016** - Abraha I, Serraino D, Giovannini G, Stracci F, Casucci P, Alessandrini G, Bidoli E, **Chiari R**, Cirocchi R, De Giorgi M, Franchini D, Vitale MF, Fusco M, Montedori A.

Validity of ICD-9-CM codes for breast, lung and colorectal cancers in three Italian administrative healthcare databases: a diagnostic accuracy study protocol.

*BMJ Open*. 2016 Mar 25;6(3):e010547. doi: 10.1136/bmjopen-2015-010547. (IF:2.562)

---

**2016** - Metro G, Ricciuti B, **Chiari R**, Baretta M, Falcinelli L, Giannarelli D, Sidoni A, Mountzios G, Crinò L, Bellezza G, Rebonato A, Ferolla P, Toschi L.

Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice.

*Lung Cancer*, vol. 95, p. 82-87, ISSN: 0169-5002, doi: 10.1016/j.lungcan.2016.03.006. (IF:3.767)

---

**2016** - Ricciuti B, Mencaroni C, Paglialunga L, Paciullo F, Crinò L, **Chiari R**, Metro G.

Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy.

*Medical Oncology*, ISSN: 1357-0560 doi: 10.1007/s12032-016-0731-2. (IF:2.486)

---

**2016** - Metro G, **Chiari R** (2017).

Preface on "Emerging treatment options for brain metastases from non-small cell lung cancer"

*Translational Lung Cancer Research*, ISSN: 2218-6751, (2017) doi: 10.21037/tlcr.2016.12.04

---

**2015** - Falcinelli L, Bellavita R, Rebonato A, **Chiari R**, Vannucci J, Puma F, Aristei C.

Bronchiolitis obliterans organizing pneumonia after radiation therapy for lung cancer: a case report.

*Tumori*. 2015 Jun 25;101(3):e88-91. doi: 10.5301/TJ.2015.14508. (IF:1.071)

---

**2015** - Metro G, Lunardi G, Floridi P, Pascali JP, Marcomigni L, **Chiari R**, Ludovini V, Crinò L, Gori S.

CSF Concentration of Crizotinib in Two ALK-Positive Non-Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment.

*Journal Of Thoracic Oncology*, ISSN: 1556-0864 2015 May;10(5):e26-7 doi: 10.1097/JTO. (IF:5.040)

---

**2015** - Verso M, **Chiari R**, Mosca S, Franco L, Fischer M, Paglialunga L, Bennati C, Scialpi M, Agnelli G.

Incidence of Ct scan-detected pulmonary embolism in patients with oncogene-addicted, advanced lung adenocarcinoma.

*Thrombosis Research*, ISSN: 0049-3848 2015 Nov;136(5):924-7. doi: 10.1016/j.thromres.2015.09.006. (IF:1.73)

---

**2015** - **Chiari R**, Metro G, Iacono D, Bellezza G, Rebonato A, Dubini A, Sperduti I, Bennati C, Paglialunga L, Burgio MA, Baglivo S, Giusti R, Minotti V, Delmonte A, Crinò L.

Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis.

*Lung Cancer*, ISSN: 0169-5002, 2015 Nov;90(2):255-60. doi: 10.1016/j.lungcan.2015.09.009. (IF:3.767)

---

**2015** - Ricciuti B, Mecca C, Cenci M, Leonardi GC, Perrone L, Mencaroni C, Crinò L, Grignani F, Baglivo S, **Chiari R**, Sidoni A, Paglialunga L, Currà MF, Murano E, Minotti V, Metro G.

miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance.

*E Cancer Medical Science*, vol. 9, ISSN: 1754-6605, 2015 Sep 2;9:569. doi: 10.3332/ecancer.2015.569.

---

**2015** - Marchetti A, Palma JF, Felicioni L, De Pas TM, **Chiari R**, Del Grammastro M, Filice G, Ludovini V, Brandes AA, Chella A, Malorgio F, Guglielmi F, De Tursi M, Santoro A, Crinò L, Buttitta F.

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients. (IF:5.040)

*Journal Of Thoracic Oncology*, ISSN: 1556-0864, 2015 Oct;10(10):1437-43. doi: 10.1097/JTO.0000000000000643.

---

**2015** - Marano L, **Chiari R**, Fabozzi A, De Vita F, Boccardi V, Roviello G, Petrioli R, Marrelli D, Roviello F, Patriti A. c-Met targeting in advanced gastric cancer: An open challenge.

*Cancer Letters*, ISSN: 0304-3835 2015 Aug 28;365(1):30-6. doi: 10.1016/j.canlet.2015.05.028. (IF:5.992)

---

**2015** - Metro G, **Chiari R**, Ricciuti B, Rebonato A, Lupattelli M, Gori S, Bennati C, Castrioto C, Floridi P, Minotti V, Chiarini P, Crinò L.

Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. EXPERT OPINION ON Pharmacotherapy, ISSN: 1465-6566 2015;16(17):2601-13. doi: 10.1517/14656566.2015.1094056. (IF:3.534)

**2015** - Iacono D, **Chiari R**, Metro G, Bennati C, Bellezza G, Cenci M, Ricciuti B, Sidoni A, Baglivo S, Minotti V, Crinò L. Future options for ALK-positive non-small cell lung cancer. (IF:3.767)

Lung Cancer, ISSN: 0169-5002, 2015 Mar;87(3):211-9. doi: 10.1016/j.lungcan.2014.12.017.

**2014** - **Chiari R**, Buttitta F, Iacono D, Bennati C, Metro G, Di Lorito A, Iezzi M, Tiseo M, Mazzoni F, Cappuzzo F, Marchetti A, Crinò L.

Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. (IF:3.434)

Clinical Lung Cancer, ISSN: 1525-7304 2014 Nov;15(6):470-4. doi: 10.1016/j.clcc.2014.06.004. Epub 2014 Jun 24.

**2014** - Landi L, Tiseo M, **Chiari R**, Ricciardi S, Rossi E, Galetta D, Novello S, Milella M, D'Incecco A, Minuti G, Tibaldi C, Salvini J, Facchinetti F, Haspinger ER, Cortinovis D, Santo A, Banna G, Catino A, GiajLevra M, Crinò L, de Marinis F, Cappuzzo F.

Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. (IF:3.434)

Clinical Lung Cancer, ISSN: 1525-7304, 2014 Nov;15(6):411-417.e4. doi: 10.1016/j.clcc.2014.07.002. Epub 2014 Aug 16.

**2014** - Metro G, **Chiari R**, Bennati C, Cenci M, Ricciuti B, Puma F, Flacco A, Rebonato A, Giannarelli D, Ludovini V, Bellezza G, Ferolla P, Minotti V, Crinò L.

Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.

Clinical Lung Cancer, ISSN: 1525-7304, 2014 Jan;15(1):86-92. doi: 10.1016/j.clcc.2013.08.002. (IF:3.434)

**2014** - **Chiari R**, Duranti S, Ludovini V, Bellezza G, Pireddu A, Minotti V, Bennati C, Crinò L

Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene. (IF:20.982)

Journal of Clinical Oncology ISSN: 0732183X 2014 Mar 20;32(9):e30-2 doi: 10.1200/JCO.2012.47.7141 Epub 2014 Jan 13

**2013** - Bellezza G, Del Sordo R, Colella R, Ludovini V, Ragusa M, Bianconi F, Ferri I, Borri F, **Chiari R**, Puma F, Crinò L, Sidoni A. (IF 2015: 2.651)

Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC).

Virchows Archiv, ISSN: 0945-6317, 2013 Nov;463(5):663-71. doi: 10.1007/s00428-013-1445-x. Epub 2013 Sep 7.

**2013** - Metro G, **Chiari R**, Baldi A, De Angelis V, Minotti V, Crinò L.

Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer.

Future Oncology, ISSN: 1479-6694, 2013 Feb;9(2):167-77. doi: 10.2217/fon.12.198. (IF:2.129)

**2013** - Ludovini V, Flacco A, Bianconi F, Ragusa M, Vannucci J, Bellezza G, **Chiari R**, Minotti V, Pistola L, Tofanetti FR, Siggillino A, Baldelli E, Sidoni A, Daddi N, Puma F, Varella-Garcia M, Crinò L.

Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients. (IF:2.824)

Cancer Chemotherapy And Pharmacology, ISSN: 0344-5704, 2013 Mar;71(3):671-80. doi: 10.1007/s00280-012-2056-y. Epub 2013 Jan 12.

**2012** - Bennati C, Russo G, **Chiari R**, Giovenali P, Bassotti G.

Colonic metastases from non-small cell lung cancer. (IF:1.455)

Rev. Esp. de Enfermedades Dig. ISSN: 1130-0108 2012 Aug;104(8):447-8.

**2012** - Ludovini V, Bianconi F, Pistola L, Pistola V, **Chiari R**, Colella R, Bellezza G, Tofanetti FR, Siggillino A, Baldelli E, Flacco A, Giuffrida D, Sidoni A, Crinò L.

Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. (IF:2.824)

Cancer Chemotherapy and Pharmacology v. 69, p. 1289-1299, ISSN: 0344-5704, 2012 doi: 10.1007/s00280-012-1829-7.

**2012** - Metro G, **Chiari R**, Duranti S, Siggillino A, Fischer MJ, Giannarelli D, Ludovini V, Bennati C, Marcomigni L, Baldi A, Giansanti M, Minotti V, Crinò L.

Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. (IF:3.767)

Lung Cancer, ISSN: 0169-5002, 2012 Oct;78(1):81-6. doi: 10.1016/j.lungcan.2012.06.005. Epub 2012 Jul 4.

**2011** - Ludovini V, Floriani I, Pistola L, Minotti V, Meacci M, **Chiari R**, Garavaglia D, Tofanetti FR, Flacco A, Siggillino A, Baldelli E, Tonato M, Crinò L.

Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. (IF:5.040)

Journal Of Thoracic Oncology, ISSN: 1556-0864, 2011 Dec;6(12):2018-26. doi: 10.1097/JTO.0b013e3182307e1f.

**2011** - Metro G, **Chiari R**, Mare M, Giannarelli D, Tofanetti FR, Minotti V, Ferraldeschi M, Giuffrida D, Marcomigni L, Bennati C, Fischer MJ, Meacci M, Bellavita R, Pistola L, Ludovini V, Crinò L.

Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation. (IF:2.824) ISSN: 0344-5704

Cancer Chemotherapy and Pharmacology, 2011 Dec;68(6):1405-12. doi: 10.1007/s00280-011-1632-x. Epub 2011 Apr 6.

- 
- 2011** - Ludovini V, Bianconi F, Pistola L, **Chiari R**, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L. (IF:5.040)  
Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.  
Journal of Thor. Oncology vol 6 p 707-715, ISSN: 15560864 2011 Apr;6(4):707-15 doi:10.1097/JTO.0b013e31820a3a6b
- 
- 2001** - Karanikas V, Colau D, Baurain JF, **Chiari R**, Thonnard J, Gutierrez-Roelens I, Goffinet C, Van Schaftingen EV, Weynants P, Boon T, Coulie PG.  
High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. (IF: 9,13)  
ISSN: 00085472 Cancer Res. 2001 May 1;61(9):3718-24. PubMed ID: 11325844
- 
- 2000** - **Chiari R**, Hames G, Stroobant V, Texier C, Maillère B, Boon T, Coulie PG.  
Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules.  
ISSN: 00085472 Cancer Res. 2000 Sep 1;60(17):4855-63. PubMed ID: 10987298 (IF: 9,13)
- 
- 1999** - **Chiari R**, Foury F, De Plaen E, Baurain JF, Thonnard J, Coulie PG.  
Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. (IF: 9,13)  
ISSN: 00085472 Cancer Res. 1999 Nov 15;59(22):5785-92. PubMed ID: 10582700
- 
- 1999** - Coulie PG, Ikeda H, Baurain JF, **Chiari R**.  
Antitumor immunity at work in a melanoma patient. (IF:4.754)  
ISSN: 0065230X Adv Cancer Res. 1999;76:213-42. PubMed ID: 10218103
- 

Pesaro 28.01.2022